Entero Healthcare Solutions Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Profit growth above 25%Exceptional itemNegative operating cash flowRelated-party transactionsResults View source PDF Explain this filing

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.4%Reaction day

₹1311.00

prior close

₹1358.90

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%-3.1% vs market

Retailing peers, median of 54sector · industry level+0.0%-2.4% vs sector

On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 2.4 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.5

10m

-3.8

15m

-2.3

30m

-4.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.4+0.7-3.1+0.0-2.4

Next day

-9.9+0.7-10.6+0.0-9.9

-8.5+0.0-8.6-1.1-7.4

-13.7-1.1-12.6-1.8-11.8

-11.9+0.0-11.9-1.2-10.7

-14.5+0.3-14.7-1.3-13.2

-14.6+1.1-15.7-1.0-13.6

15d

-15.3+4.9-20.1+0.1-15.3

-8.5+5.3-13.8-2.2-6.3

-2.6+6.9-9.5-2.6+0.0

+25.5+11.9+13.6-2.5+28.0

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 54Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Entero Healthcare reported mixed FY2026 results. On a consolidated basis, revenue grew 29% to Rs. 65.91 billion from Rs. 50.96 billion, with PAT rising 36% to Rs. 1,458.4 million versus Rs. 1,074.3 million. However, standalone revenue declined 15% to Rs. 3,482 million from Rs. 4,087 million, though standalone PAT improved to Rs. 268.8 million from Rs. 191.8 million. An exceptional item of Rs. 81.78 million (consolidated) was recognized due to incremental employee benefit obligations under the New Labour Codes. The company completed multiple acquisitions during the year, including Ramson Medical, Sat K Pharma, Well Wisher Pharma, and others, contributing to consolidated growth. Standalone operating cash flow was negative at Rs. 581 million. Auditors MSKA & Associates gave an unmodified (clean) opinion.

Likely market impact

Consolidated performance shows strong growth driven by acquisitions, but standalone revenue decline and negative operating cash flow may raise concerns about underlying business quality. The exceptional labour code charge is a one-time item.